Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease

Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease

Saved in:

Bibliographic Details
Main Authors:	Elias John Elenjickal, Anna T. Valson, Santosh Varughese, Lloyd Vincent, Edwin Fernando, Gopalakrishnan Natarajan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Pharmacology
Subjects:	diabetes mellitus pathomechanisms oxidative stress SGLT 2 inhibitor GLP-1 recepter agonist astrgaloside IV
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1531748/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01)

Effect of sex on sodium‐glucose co‐transporter‐2 antagonists and glucagon‐like peptide‐1 agonists in heart failure
by: Mevin A. Philip, et al.
Published: (2024-12-01)

Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
by: Mohsina Patwekar, et al.
Published: (2025-01-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
by: Ioannis Bellos, et al.
Published: (2024-12-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Biotechnology Revolution Shaping the Future of Diabetes Management
by: Nilima Rajpal Kundnani, et al.
Published: (2024-12-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
by: Jakub Waszczyński, et al.
Published: (2025-01-01)

Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
by: Basavana Goudra, et al.
Published: (2024-12-01)

PREVENT Risk Score and Use of Cardioprotective Agents in Type 2 Diabetes: An Analysis of NHANES 2013 to 2020
by: Lucas A. Mavromatis, et al.
Published: (2024-11-01)

Differential contributions of the gut microbiota and metabolome to pathomechanisms in ulcerative colitis: an in vitro analysis
by: Jonas Poppe, et al.
Published: (2024-12-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024-11-01)

Genomic composition and pathomechanisms of porcine circoviruses: A review
by: Yong-Yu Gao, et al.
Published: (2024-12-01)

Ewing sarcoma – pathomechanisms, standard treatment and new therapeutic perspectives
by: Wojciech Zezuliński, et al.
Published: (2025-01-01)

The impact of glycolysis on ischemic stroke: from molecular mechanisms to clinical applications
by: Yingquan Liu, et al.
Published: (2025-01-01)

Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
by: Dariusz Popiela, et al.
Published: (2025-01-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes
by: Kevin Y. Heo, BS, et al.
Published: (2024-12-01)

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
by: Zhiyuan Cheng, et al.
Published: (2024-10-01)

Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
by: Bea Campforts, et al.
Published: (2024-11-01)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024-11-01)

Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
by: Yuxin Zhang, et al.
Published: (2025-01-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
by: Mohammed Ali Gameil, et al.
Published: (2024-12-01)

Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
by: Przemysław Witek, et al.
Published: (2024-12-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
by: Hiroya Kitsunai, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)